Mechanisms of progressive renal disease: role of angiotensin II, cyclooxygenase products and nitric oxide (2002)
- Authors:
- USP affiliated authors: ZATZ, ROBERTO - FM ; FUJIHARA, CLARICE KAZUE - FM
- Unidade: FM
- Subjects: ANGIOTENSINA II; ÓXIDO NÍTRICO
- Language: Inglês
- Imprenta:
- Source:
- Título: Journal of Hypertension
- Volume/Número/Paginação/Ano: v. 20, Suppl. 3, p. S37-S44, June, 2002
-
ABNT
ZATS, Roberto e FUJIHARA, Clarice Kazue. Mechanisms of progressive renal disease: role of angiotensin II, cyclooxygenase products and nitric oxide. Journal of Hypertension, v. 20, p. S37-S44, 2002Tradução . . Acesso em: 10 jan. 2026. -
APA
Zats, R., & Fujihara, C. K. (2002). Mechanisms of progressive renal disease: role of angiotensin II, cyclooxygenase products and nitric oxide. Journal of Hypertension, 20, S37-S44. -
NLM
Zats R, Fujihara CK. Mechanisms of progressive renal disease: role of angiotensin II, cyclooxygenase products and nitric oxide. Journal of Hypertension. 2002 ; 20 S37-S44.[citado 2026 jan. 10 ] -
Vancouver
Zats R, Fujihara CK. Mechanisms of progressive renal disease: role of angiotensin II, cyclooxygenase products and nitric oxide. Journal of Hypertension. 2002 ; 20 S37-S44.[citado 2026 jan. 10 ] - The inflammatory component in progressive renal disease: are interventions possible
- An extremely high dose of losartan affords superior renoprotection in the remnant model
- Chronic inhibition of nuclear factor-kB attenuates renal injury in the 5/6 renal ablation model
- Effects of an endothelin et receptor antagonist on experimental fk506 induced acute renal dysfunction
- Hypertension and progressive renal injury induced by salt overload in rats preconditioned by temporary nitric oxide (NO) inhibition
- O efeito do tratamento tardio com alta dose de losartan (L) no modelo de ablação renal de 5/6 (NX)
- Extremely high doses of Losartan (L) prevent renal injuryin the remnant kidney model (NX) by an antiinflammatory rather than glomerular hemodynamic effect
- Early temporary with the AT1 blocker Losartan (L), in high dose or associated with Mycophenolate Mofetil (MMF), limits future injury in the remnant kidney
- Early Brief Treatment with Losartan plus Mycophenolate Mofetil Provides Lasting Renoprotection in a Renal Ablation Model
- Effect of combined therapy with losartan and furosemide in rats with 5/6 nephrectomy
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
